NIH Grants Exclusive License for Autoimmune CAR Therapy
Published Date: 2/13/2026
Notice
Summary
The National Cancer Institute plans to give Kyverna Therapeutics an exclusive license to use a special CAR therapy that helps treat or prevent autoimmune diseases caused by B cells. This means Kyverna will be the only company allowed to develop and sell this innovative treatment. If you want to comment or apply for a license, you need to act by March 2, 2026.
Analyzed Economic Effects
3 provisions identified: 2 benefits, 0 costs, 1 mixed.
Exclusive License to Kyverna for Anti‑CD19 CARs
The National Cancer Institute is contemplating granting Kyverna Therapeutics an exclusive patent license (which may be worldwide) for developing, producing, and commercializing an anti‑CD19 CAR immunotherapy that uses either a non‑viral synthetic nanoparticle system or a viral system (excluding lentiviral) that encapsulates mRNA or DNA encoding a CAR with the Hu19 CDR sequences, for the treatment or prevention of B cell mediated autoimmune diseases.
Deadline to Comment or Apply for License
If you want to comment on or apply for this exclusive license, written comments and/or license applications must be received by the NCI Technology Transfer Center on or before March 2, 2026. License applications filed in response to this notice will be treated as objections to the grant and are presumed to contain business confidential information.
Field of Use Carve-Outs and Royalty Requirement
The contemplated exclusive license would exclude anti‑CD19 CAR approaches that use CRISPR/Cas9‑edited allogeneic T lymphocytes and autologous T lymphocytes engineered by lentivirus, and it does not include CAR constructs that exclusively use the FMC63 antigen binding domain. The prospective exclusive license will be royalty bearing.
Personalized for You
How does this regulation affect your finances?
Personalize government policy and PRIA will tell you what this federal register document means for your household, plus every other regulation we track. PRIA reads each provision against your financial profile to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-16683, Proposed Collection; 60-Day Comment Request; Data Use Certification for the NIH National Institute on Drug Abuse Data Share Site
The purpose of this notice is to inform the public of the information collection requirement for the NIDA Data Share, the data use terms and conditions, and to request a progress report statement at the time of renewal. In compliance with the requirement of the Paperwork Reduction Act of 1995 to provide opportunity for public comment on proposed data collection projects, the National Institute on Drug Abuse (NIDA) will publish periodic summaries of proposed projects to be submitted to the Office of Management and Budget (OMB) for review and approval.
2026-16544, Government-Owned Inventions; Availability for Licensing
The inventions listed below are owned by an agency of the U.S. Government and are available for licensing to achieve expeditious commercialization of results of federally-funded research for the benefit of the public health.
2026-16440, NIH Owned Invention Available for License: Soluble Tissue Factor, a Novel Target, and Antibodies, for Diagnosis, Prevention and Treatment of Thrombosis and Related Conditions
Scientists at the National Cancer Institute (NCI) have discovered a novel therapeutic, diagnostic and prognostic target for thrombosis: Soluble Tissue Factor (sTF). NCI has generated first-in- class antibodies and platform selectively neutralizing pathological coagulation while preserving normal hemostasis. This platform technology can be used to prevent, diagnose and treat pathological thrombosis caused by a variety of clinical conditions-including cancer, sepsis, infectious diseases (e.g., COVID), autoimmune disorders, trauma, heart conditions and inflammatory conditions. It offers a much more sensitive and specific test of thrombosis than the current D-dimer test. It may be applicable to any clinical condition which induces necroptosis, pyroptosis and NETtosis, such as cancer, neurodegenerative disease, ischemia-reperfusion and acute injuries, traumatic injuries, bacterial and viral infections, cardiovascular conditions, and atherosclerosis, inflammatory, autoimmune conditions, and others.
2026-16071, Proposed Collection; 60-Day Comment Request: The Impact of Clinical Research Training and Medical Education at the Clinical Center on Physician Careers in Academia and Clinical Research (Clinical Center)
In compliance with the requirement of the Paperwork Reduction Act of 1995, for opportunity for public comment on proposed data collection projects, the Clinical Center, the National Institutes of Health (NIH) will publish periodic summaries of proposed projects to be submitted to the Office of Management and Budget (OMB) for review and approval.
2026-15565, Proposed Collection; 60-Day Comment Request, Data Use Certification for the NIH Brain Development Cohorts (NBDC) Data Hub, (National Institute on Drug Abuse)
In compliance with the requirement of the Paperwork Reduction Act of 1995 to provide opportunity for public comment on proposed data collection projects, the National Institute on Drug Abuse (NIDA) will publish periodic summaries of proposed projects to be submitted to the Office of Management and Budget (OMB) for review and approval. The purpose of this revision is to update instructions for the Research Data Use Statement and the Progress Report, and to add new instructions for attesting to National Institute of Standards & Technology (NIST) security compliance, and for a Project Close-out at the time of project completion. Burden levels remain unchanged.
2026-14964, Center for Scientific Review; Notice of Closed Meeting
The Center for Scientific Review is holding a closed virtual meeting on August 19, 2026, to review neuroscience career development grant applications. This meeting is private to protect sensitive info like trade secrets and personal details. Researchers applying for these grants should note the date, as funding decisions could impact their projects and careers.
Previous / Next Documents
Previous: 2026-02906, Government Owned Inventions Available for License: Gait Assistance Systems and Methods of Control Thereof
The NIH is offering a license for a smart, robot-powered system that helps people with movement problems walk better by adapting to their unique way of moving. This invention uses machine learning to personalize support in real-time, making walking easier and more natural for kids and adults with conditions like cerebral palsy. Companies interested in bringing this tech to market should act soon to help improve lives and tap into a promising new market.
Next: 2026-02908, Bulk Manufacturer of Controlled Substances Application: Scottsdale Research Institute
Scottsdale Research Institute wants to make large amounts of marijuana and related substances for clinical trials and customers. People who already make or use these drugs can comment or ask for a hearing by April 14, 2026. This move could speed up research and distribution, but no other drug activities are allowed under this registration.